Please enable JS

ARTICLES & TESTIMONIALS

Daily Record – Letter: Bill could bring relief to more patients

Jul 10/50SN Staff/ Advocates in the news

On June 8, the state Senate debated House No. 2477/Senate No. 1705, which provides a pathway in New Jersey for access to lower-cost mimic therapies of expensive biologic drugs.

READ MORE

NJ Spotlight – Op/Ed – Why Would Drug-Store Lobby Back Bill That Conceals ‘Biosimilar’ Switch?

Jul 10/50SN Staff/ GHLF in the news

The bond between patients and healthcare providers has always been based on trust and transparency

READ MORE

International Business Times – What Are Biosimilars? Zarxio, First Drug Of Its Kind Approved In US

Jul 10/50SN Staff/ GHLF in the news

The FDA’s approval of Zarxio, the first biosimilar product authorized for use in the United States, led to a flurry of predictions Friday about billions of dollars in savings and expanded access to treatment for patients. But what exactly are biosimilars, and why are they being hailed in this way?

READ MORE

Washington State Wire – Op/Ed – Biosimilar Drugs Require More Transparent Communication Between Patient and Pharmacist: SB 5935 Needs Work

Jul 10/50SN Staff/ GHLF in the news

Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products.

READ MORE

DENVER BUSINESS JOURNAL – Cheaper generic biotech drugs loom as ‘biosimilars’ law advances in Colorado Legislature

Jul 10/50SN Staff/ Advocates in the news

The U.S. Food & Drug Administration approved the first generic version of a biotech drug for domestic sale Friday, hours after Colorado state legislators wrestled with how to let pharmacists handle cheaper biotech drug knockoffs.

READ MORE